Dario Paggiarino - Eyepoint Pharmaceuticals Senior Officer

All Insiders . USA . 
Stock . Eyepoint Pharmaceuticals . Stakeholders . Insider . Dario Paggiarino
EYPT Stock  USD 9.23  0.28  3.13%   

Executive

Dario Paggiarino is Senior Officer of Eyepoint Pharmaceuticals
Age 67
Address 480 Pleasant Street, Watertown, MA, United States, 02472
Phone617 926 5000
Webhttps://eyepointpharma.com

Dario Paggiarino Latest Insider Activity

Tracking and analyzing the buying and selling activities of Dario Paggiarino against Eyepoint Pharmaceuticals stock is an integral part of due diligence when investing in Eyepoint Pharmaceuticals. Dario Paggiarino insider activity provides valuable insight into whether Eyepoint Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Eyepoint Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eyepoint Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
 
Dario Paggiarino over six months ago
Disposition of 14000 shares by Dario Paggiarino of Eyepoint Pharmaceuticals subject to Rule 16b-3

Eyepoint Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.3139) % which means that it has lost $0.3139 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7468) %, meaning that it created substantial loss on money invested by shareholders. Eyepoint Pharmaceuticals' management efficiency ratios could be used to measure how well Eyepoint Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.21 in 2024. Return On Capital Employed is likely to drop to -0.26 in 2024. At this time, Eyepoint Pharmaceuticals' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 372.9 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 17.4 M in 2024.
Eyepoint Pharmaceuticals currently holds 5.47 M in liabilities with Debt to Equity (D/E) ratio of 0.3, which may suggest the company is not taking enough advantage from borrowing. Eyepoint Pharmaceuticals has a current ratio of 6.04, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Eyepoint Pharmaceuticals' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Kristen MSSoleno Therapeutics
55
Marcia BelvinCytomX Therapeutics
N/A
Dana MDCrinetics Pharmaceuticals
68
Patricia MPHSoleno Therapeutics
58
Marc CPACrinetics Pharmaceuticals
45
James TaylorAchilles Therapeutics PLC
63
Daniel HoodAchilles Therapeutics PLC
N/A
Lauren BudesheimSoleno Therapeutics
N/A
Marc WilsonCrinetics Pharmaceuticals
45
Kristi ElliottCapricor Therapeutics
N/A
Richard ColonnoAssembly Biosciences
74
Jesse SchumakerSoleno Therapeutics
N/A
Michael MDSoleno Therapeutics
50
Lee SternAchilles Therapeutics PLC
N/A
Dawn BensonCytomX Therapeutics
N/A
Amy CFAAssembly Biosciences
N/A
Edward SamuelAchilles Therapeutics PLC
N/A
Garlan AdamsCrinetics Pharmaceuticals
N/A
Gayathri DiwakarCrinetics Pharmaceuticals
N/A
Robert MBBSInstil Bio
N/A
Dr MBASoleno Therapeutics
N/A
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. Eyepoint Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 122 people. Eyepoint Pharmaceuticals (EYPT) is traded on NASDAQ Exchange in USA. It is located in 480 Pleasant Street, Watertown, MA, United States, 02472 and employs 121 people. Eyepoint Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Return On Equity-0.75
Return On Asset-0.31

Eyepoint Pharmaceuticals Leadership Team

Elected by the shareholders, the Eyepoint Pharmaceuticals' board of directors comprises two types of representatives: Eyepoint Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eyepoint. The board's role is to monitor Eyepoint Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eyepoint Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eyepoint Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
David Jones, Senior Officer
Jay MD, Chief Officer
Michael Pine, Chief Officer
Ramiro MD, Chief Officer
Nancy Lurker, President CEO, Independent Director
Dr MS, Interim Director
Jennifer Leonard, Chief IT
Anna Kluczewska, President Ltd
George Elston, Chief Officer
Dario Paggiarino, Senior Officer
Ron Esq, Chief Secretary
Dario MD, Executive Officer
Said Saim, Chief Officer
Isabelle Lefebvre, Chief Officer
Marcia SellosMoura, Senior Leadership
Michael Maciocio, Senior Operations
George CPA, Executive CFO
David MA, Senior Officer

Eyepoint Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eyepoint Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.75
Return On Asset-0.31
Profit Margin(2.27) %
Operating Margin(3.11) %
Current Valuation378.98 M
Shares Outstanding68.25 M
Shares Owned By Insiders1.14 %
Shares Owned By Institutions93.43 %
Number Of Shares Shorted9.68 M
Price To Earning(2.82) X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY